MedDataX Logo

A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT ID: NCT06176768

Last Updated: 2025-10-15

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-06

Study Completion Date

2025-05-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3361237 in Participants With Psoriasis

NCT04975295

Psoriasis
COMPLETED PHASE1

A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT06602219

Plaque Psoriasis
COMPLETED PHASE2

A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

NCT04152382

Psoriasis
TERMINATED PHASE1

A Phase 3 Study in Participants With Moderate to Severe Psoriasis

NCT01474512

Psoriasis
COMPLETED PHASE3

A Study of LY3471851 in Participants With Psoriasis

NCT04119557

Psoriasis
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plaque Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3972406

Participants received an oral dose of LY3972406 for 12 weeks.

Group Type EXPERIMENTAL

LY3972406

Intervention Type DRUG

Administered orally

Placebo

Participants received an oral dose of placebo for 12 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3972406

Administered orally

Intervention Type DRUG

Placebo

Administered orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline
* Have venous access sufficient to allow for blood sampling
* Are able to swallow oral medication

Exclusion Criteria

* Have any other skin conditions, excluding plaque psoriasis
* Have a current or recent acute, active infection
* Have manifestations of other autoimmune diseases, such as systemic lupus erythematosus.
* Are lactating or breastfeeding women
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 on - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Role: STUDY_DIRECTOR

Eli Lilly and Company

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dermatology Research Associates

Los Angeles, California, United States

Site Status

Clinical Science Institute

Santa Monica, California, United States

Site Status

Driven Research

Coral Gables, Florida, United States

Site Status

Conquest Research

Winter Park, Florida, United States

Site Status

Psoriasis Treatment Center of Central New Jersey

East Windsor, New Jersey, United States

Site Status

Schweiger Dermatology Group

Hackensack, New Jersey, United States

Site Status

Metropolitan Dermatology - Clark

Kenilworth, New Jersey, United States

Site Status

Accellacare - Winston-Salem

Winston-Salem, North Carolina, United States

Site Status

Remington-Davis, Inc

Columbus, Ohio, United States

Site Status

DermDox Centers for Dermatology

Camp Hill, Pennsylvania, United States

Site Status

Center for Clinical Studies

Houston, Texas, United States

Site Status

Austin Institute for Clinical Research

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

J4H-MC-FVAA

Identifier Type: OTHER

Identifier Source: secondary_id

2023-504485-39-00

Identifier Type: OTHER

Identifier Source: secondary_id

18692

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226 ACTIVE_NOT_RECRUITING PHASE3
A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis
NCT06808815 COMPLETED PHASE1
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)
NCT01646177 COMPLETED PHASE3
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)
NCT01597245 COMPLETED PHASE3
A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis
NCT03418493 COMPLETED PHASE1
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
NCT02561806 COMPLETED PHASE3
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
NCT02513550 COMPLETED PHASE3
A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
NCT05357755 COMPLETED PHASE2
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
NCT03073200 COMPLETED PHASE3
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
NCT01490632 COMPLETED PHASE2
Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis
NCT00396422 COMPLETED PHASE2
A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
NCT05223868 COMPLETED PHASE2
A Study for Adults With Plaque Psoriasis
NCT01018810 TERMINATED PHASE2
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis
NCT02899988 COMPLETED PHASE2
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
NCT01729754 COMPLETED PHASE3
A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
NCT03364309 COMPLETED PHASE3
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
NCT03482011 COMPLETED PHASE3
Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)
NCT02346240 COMPLETED PHASE3
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
NCT05730725 COMPLETED PHASE2
A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT05364554 COMPLETED PHASE2
A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
NCT02387801 COMPLETED PHASE3
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
NCT03556202 TERMINATED PHASE3
Bimekizumab in Plaque Psoriasis
NCT06336343 RECRUITING PHASE4
A Study in Participants With Moderate to Severe Psoriasis
NCT01107457 COMPLETED PHASE2
Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?
NCT06742333 RECRUITING PHASE2